A Randomized Double-Blind Controlled Trial of Everolimus in Children and Adolescents With PTEN Mutations (RAD001XUS257T)
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Multiple hamartoma syndrome
- Focus Adverse reactions
- Acronyms RAD001XUS257T
- 11 May 2017 Status changed from not yet recruiting to recruiting.
- 02 Feb 2017 Planned initiation date changed from 1 Jan 2017 to 1 Mar 2017.
- 16 Dec 2016 New trial record